Christopher James analyst

Currently out of the existing stock ratings of Christopher James, 16 are a BUY (94.12%), 1 are a HOLD (5.88%).

Christopher James

Work Performance Price Targets & Ratings Chart

Analyst Christopher James, currently employed carries an average stock price target met ratio of 40% that have a potential upside of 32.05% achieved within 75 days. Previously, Christopher James worked at LADENBURG, B. RILEY.

Christopher James’s has documented 30 price targets and ratings displayed on 5 stocks. The coverage was on the Healthcare sector.

Most recent stock forecast was given on ACHN, Achillion Pharmaceuticals at 12-Sep-2017.

Wall Street Analyst Christopher James

Analyst best performing recommendations are on CORT (CORCEPT THERAPEUTICS ORPORATED).
The best stock recommendation documented was for CORT (CORCEPT THERAPEUTICS ORPORATED) at 7/18/2017. The price target of $20 was fulfilled within 79 days with a profit of $7.59 (61.16%) receiving and performance score of 7.74.

Average potential price target upside

ACHN Achillion Pharmaceuticals ALNY Alnylam Pharmaceuticals CORT Corcept Therapeutics orporated TRVN Trevena ZFGN Zafgen

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Hold

2

$1.82 (1011.11%)

5

5 years 2 months 16 days ago

2/3 (66.67%)

$-0.96 (-32.43%)

528

Hold

4

6 years 5 months 11 days ago

4/4 (100%)

$-0.81 (-16.84%)

106

Buy

5

$4.82 (2677.78%)

6

6 years 7 months 8 days ago

0/4 (0%)

$2.14 (74.83%)

Buy

10

6 years 10 months 7 days ago

0/2 (0%)

$5.79 (137.53%)

Hold

4

$3.82 (2122.22%)

5

6 years 10 months 8 days ago

6/7 (85.71%)

$0.17 (4.44%)

49

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What Year was the first public recommendation made by Christopher James?

On 2015

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?